{"protocolSection": {"identificationModule": {"nctId": "NCT01658579", "orgStudyIdInfo": {"id": "PDY12777"}, "secondaryIdInfos": [{"id": "U1111-1130-3593", "type": "OTHER", "domain": "UTN"}], "organization": {"fullName": "Sanofi", "class": "INDUSTRY"}, "briefTitle": "Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin", "officialTitle": "A 16-week, Randomized, Open-label, Controlled Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine Versus Lantus in Patients With Type 1 Diabetes Mellitus"}, "statusModule": {"statusVerifiedDate": "2015-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-08"}, "primaryCompletionDateStruct": {"date": "2013-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-07-26", "studyFirstSubmitQcDate": "2012-08-02", "studyFirstPostDateStruct": {"date": "2012-08-07", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-03-24", "resultsFirstSubmitQcDate": "2015-05-05", "resultsFirstPostDateStruct": {"date": "2015-05-07", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2014-04-08", "dispFirstSubmitQcDate": "2014-04-08", "dispFirstPostDateStruct": {"date": "2014-05-02", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-05-07", "lastUpdatePostDateStruct": {"date": "2015-06-01", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Sanofi", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "Primary Objective:\n\n* To compare the glucose control during treatment with a new formulation of insulin glargine and Lantus in adult participants with type 1 diabetes mellitus\n\nSecondary Objectives:\n\n* To compare a new formulation of insulin glargine and Lantus given in the morning or in the evening\n* To compare the incidence and frequency of hypoglycemic episodes\n* To assess the safety and tolerability of the new formulation of insulin glargine", "detailedDescription": "* Up to 4-week screening period;\n* 16-week open-label comparative efficacy and safety treatment period;\n* 4-week post-treatment safety follow-up period."}, "conditionsModule": {"conditions": ["Type 1 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 59, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "HOE901-U300 Morning Then Evening", "type": "EXPERIMENTAL", "description": "HOE901-U300 (new insulin glargine 300 units per milliliter \\[U/mL\\]) subcutaneous (SC) injection once daily in morning for 8 weeks during treatment period A, followed by once daily in evening for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 millimole per liter (mmol/L).", "interventionNames": ["Drug: HOE901-U300 (new formulation of insulin glargine)"]}, {"label": "HOE901-U300 Evening Then Morning", "type": "EXPERIMENTAL", "description": "HOE901-U300 (new insulin glargine 300 U/mL) SC injection once daily in evening for 8 weeks during treatment period A, followed by once daily in morning for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 mmol/L.", "interventionNames": ["Drug: HOE901-U300 (new formulation of insulin glargine)"]}, {"label": "Lantus Morning Then Evening", "type": "ACTIVE_COMPARATOR", "description": "Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily in morning for 8 weeks during treatment period A, followed by once daily in evening for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 mmol/L.", "interventionNames": ["Drug: Lantus (insulin glargine)"]}, {"label": "Lantus Evening Then Morning", "type": "ACTIVE_COMPARATOR", "description": "Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily in evening for 8 weeks during treatment period A, followed by once daily in morning for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 mmol/L.", "interventionNames": ["Drug: Lantus (insulin glargine)"]}], "interventions": [{"type": "DRUG", "name": "HOE901-U300 (new formulation of insulin glargine)", "armGroupLabels": ["HOE901-U300 Evening Then Morning", "HOE901-U300 Morning Then Evening"]}, {"type": "DRUG", "name": "Lantus (insulin glargine)", "armGroupLabels": ["Lantus Evening Then Morning", "Lantus Morning Then Evening"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percentage of Time in Target Plasma Glucose Range (4.4-7.8 mmol/L [80-140 mg/dL])", "description": "Percentage of time with glucose within glycemic range (4.4-7.8 mmol/L) was assessed by the total time within glycemic range divided by the length of the assessment interval.", "timeFrame": "Up to Week 16 (assessed at Weeks 7-8 in Period A and Weeks 15-16 in Period B)"}], "secondaryOutcomes": [{"measure": "Percentage of Time Above the Upper Limit of Glycemic Range (Greater Than [>] 7.8 mmol/L [(140 mg/dL])", "description": "Percentage of time with glucose above the upper limit of glycemic range (\\>7.8 mmol/L) was assessed by the total time above the upper limit of glycemic range divided by the length of the assessment interval.", "timeFrame": "Up to Week 16 (assessed at Weeks 7-8 in Period A and Weeks 15-16 in Period B)"}, {"measure": "Percentage of Time Below The Lower Limit of Glycemic Range (<4.4 mmol/L [80 mg/dL])", "description": "Percentage of time with glucose below the lower limit of glycemic range (\\<4.4 mmol/L) was assessed by the total time below the lower limit of glycemic range divided by the length of the assessment interval.", "timeFrame": "Up to Week 16 (assessed at Weeks 7-8 in Period A and Weeks 15-16 in Period B)"}, {"measure": "Evaluation of Diurnal Glucose Exposure, Variability, and Stability", "description": "The diurnal glucose exposure is measured as the average diurnal glucose concentration, diurnal glucose variability is measured by interquartile range (IQR), that is, average distance between the 25th and the 75th point-wise percentiles and diurnal glucose stability is assessed in terms of the mean absolute rate of change (mmol/l), that is, the area under the absolute rate of change of the median curve (based on the median point values between two adjacent hourly basket intervals), divided by the length of the assessment interval.", "timeFrame": "Up to Week 16 (assessed at Weeks 7-8 in Period A and Weeks 15-16 in Period B)"}, {"measure": "Percentage of Time in Target Plasma Glucose Range (4.4-7.8 mmol/L [80-140 mg/dL]) in the Last Four Hours of Each Dosing Interval at Weeks 7 and 8 in Period A and Weeks 15 and 16 in Period B", "description": "Percentage of time with glucose within glycemic range (4.4-7.8 mmol/L) was assessed by the total time within glycemic range divided by the length of the assessment interval.", "timeFrame": "Weeks 7-8 in Period A and Weeks 15-16 in Period B"}, {"measure": "Change in HbA1c From Baseline to Week 8 and 16", "timeFrame": "Baseline, Week 8, 16"}, {"measure": "Change in Fasting Plasma Glucose (FPG) From Baseline to Week 8 and 16", "timeFrame": "Baseline, Week 8, 16"}, {"measure": "Change in Average 7-Point Self-Monitored Plasma Glucose (SMPG) Profile From Baseline to Week 8 and 16", "description": "Change in average of 7-point SMPG. 7-point SMPG was assessed starting with a measurement at before breakfast and 2 hours after breakfast\u037e before and 2 hours after lunch\u037e before and 2 hours after dinner\u037e at bedtime.", "timeFrame": "Baseline, Week 8, 16"}, {"measure": "Change in Basal Insulin Daily Dose From Baseline to Week 8 and 16", "timeFrame": "Baseline, Week 8, 16"}, {"measure": "Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline Up to Week 16", "description": "Hypoglycemia events were Severe hypoglycemia (an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions)\u037e Documented symptomatic hypoglycemia (typical symptoms of hypoglycemia with plasma glucose level of \\<=3.9 mmol/L \\[70 mg/dL\\])\u037e Asymptomatic hypoglycemia (no typical symptoms of hypoglycemia but plasma glucose level \\<=3.9 mmol/L)\u037e Probable symptomatic hypoglycemia (an event during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination, but was presumably caused by a plasma glucose level \\<=3.9 mmol/L, symptoms treated with oral carbohydrate without a test of plasma glucose)\u037e Relative hypoglycemia (an event during which the person with diabetes reported any of the typical symptoms of hypoglycemia, and interpreted the symptoms as indicative of hypoglycemia, but plasma glucose level \\>3.9 mmol/L)\u037e Severe and/or confirmed a hypoglycemia (plasma glucose \\<=3.9 mmol/L).", "timeFrame": "Up to Week 16"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria :\n\n* Participants with Type 1 diabetes mellitus\n\nExclusion criteria:\n\n* HbA1c greater than (\\>) 9% (at screening)\n* Participants receiving \\>0.5 U/kg body weight basal insulin in the last 30 days prior to screening visit\n* Participants not on stable insulin dose (+/- 20% total basal insulin dose) in the last 30 days prior to screening visit\n* Less than 1 year on any basal plus mealtime insulin\n* Participants using pre-mix insulins, human regular insulin as mealtime insulin and/or any antidiabetic drugs other than basal insulin and mealtime analogue insulin in the last 3 months before screening visit\n* Use of an insulin pump in the last 6 months before screening visit;\n* Any contraindication to use of insulin glargine as defined in the national product label\n* Not willing to inject insulin glargine as assigned by the randomization process once daily in the morning or evening\n* Hospitalization for diabetic ketoacidosis or history of severe hypoglycemia (requiring 3rd party assistance) in the last 6 months prior to randomization\n* Initiation of any glucose-lowering agents in the last 3 months before screening visit\n* Weight change of greater than equal to (\\>=) 5 kg during the last 3 months prior to screening visit\n* Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic retinopathy or macular edema likely to require laser, surgical treatment or injectable drugs during the study period\n\nThe above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "70 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Clinical Sciences & Operations", "affiliation": "Sanofi", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Investigational Site Number 840002", "city": "Temecula", "state": "California", "zip": "92591", "country": "United States", "geoPoint": {"lat": 33.49364, "lon": -117.14836}}, {"facility": "Investigational Site Number 840001", "city": "Minneapolis", "state": "Minnesota", "zip": "55416", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "Investigational Site Number 840003", "city": "Portland", "state": "Oregon", "zip": "97201-3098", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}]}, "referencesModule": {"references": [{"pmid": "28115474", "type": "DERIVED", "citation": "Bergenstal RM, Bailey TS, Rodbard D, Ziemen M, Guo H, Muehlen-Bartmer I, Ahmann AJ. Comparison of Insulin Glargine 300 Units/mL and 100 Units/mL in Adults With Type 1 Diabetes: Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening Injections. Diabetes Care. 2017 Apr;40(4):554-560. doi: 10.2337/dc16-0684. Epub 2017 Jan 23."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A total of 85 participants were screened, of whom 26 participants were screen failures and 59 participants were randomized. The data for outcome measures was planned to be reported for combined reporting arms (HOE901-U300 Combined and Lantus Combined).", "groups": [{"id": "FG000", "title": "HOE901-U300 Morning Then Evening", "description": "HOE901-U300 (new insulin glargine 300 units per milliliter \\[U/mL\\]) subcutaneous (SC) injection once daily in morning for 8 weeks during treatment period A, followed by once daily in evening for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 millimole per liter (mmol/L) (80-130 milligram per deciliter \\[mg/dL\\])."}, {"id": "FG001", "title": "HOE901-U300 Evening Then Morning", "description": "HOE901-U300 SC injection once daily in evening for 8 weeks during treatment period A, followed by once daily in morning for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 mmol/L (80-130 mg/dL)."}, {"id": "FG002", "title": "Lantus Morning Then Evening", "description": "Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily in morning for 8 weeks during treatment period A, followed by once daily in evening for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 mmol/L (80-130 mg/dL)."}, {"id": "FG003", "title": "Lantus Evening Then Morning", "description": "Lantus SC injection once daily in evening for 8 weeks during treatment period A, followed by once daily in morning for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 mmol/L (80-130 mg/dL)."}], "periods": [{"title": "Treatment Period A", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "15"}, {"groupId": "FG002", "numSubjects": "15"}, {"groupId": "FG003", "numSubjects": "14"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "15"}, {"groupId": "FG002", "numSubjects": "14"}, {"groupId": "FG003", "numSubjects": "13"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Treatment Period B", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "15"}, {"groupId": "FG002", "numSubjects": "14"}, {"groupId": "FG003", "numSubjects": "13"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "15"}, {"groupId": "FG002", "numSubjects": "14"}, {"groupId": "FG003", "numSubjects": "12"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Randomized population: all screened participants (who originally met inclusion criteria and signed informed consent) allocated to a treatment arm and recorded in Interactive Voice/Web Response System (IVRS/IWRS) database, regardless of whether treatment was used or not. Participants were analyzed in treatment arm to which they were randomized.", "groups": [{"id": "BG000", "title": "HOE901-U300 Morning Then Evening", "description": "HOE901-U300 SC injection once daily in morning for 8 weeks during treatment period A, followed by once daily in evening for 8 weeks during treatment period B."}, {"id": "BG001", "title": "HOE901-U300 Evening Then Morning", "description": "HOE901-U300 SC injection once daily in evening for 8 weeks during treatment period A, followed by once daily in morning for 8 weeks during treatment period B."}, {"id": "BG002", "title": "Lantus Morning Then Evening", "description": "Lantus SC injection once daily in morning for 8 weeks during treatment period A, followed by once daily in evening for 8 weeks during treatment period B."}, {"id": "BG003", "title": "Lantus Evening Then Morning", "description": "Lantus SC injection once daily in evening for 8 weeks during treatment period A, followed by once daily in morning for 8 weeks during treatment period B."}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "15"}, {"groupId": "BG003", "value": "14"}, {"groupId": "BG004", "value": "59"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "43.6", "spread": "14.6"}, {"groupId": "BG001", "value": "46.2", "spread": "15.9"}, {"groupId": "BG002", "value": "39.7", "spread": "12.5"}, {"groupId": "BG003", "value": "47.6", "spread": "14.1"}, {"groupId": "BG004", "value": "44.2", "spread": "14.3"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "10"}, {"groupId": "BG004", "value": "27"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "11"}, {"groupId": "BG003", "value": "4"}, {"groupId": "BG004", "value": "32"}]}]}]}, {"title": "Body Mass Index (BMI)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kilogram per square meter (kg/m^2)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "27.5", "spread": "4.9"}, {"groupId": "BG001", "value": "27.4", "spread": "5.0"}, {"groupId": "BG002", "value": "28.3", "spread": "6.2"}, {"groupId": "BG003", "value": "26.1", "spread": "5.1"}, {"groupId": "BG004", "value": "27.3", "spread": "5.3"}]}]}]}, {"title": "Glycated Hemoglobin (HbA1c)", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Less Than (<) 8", "categories": [{"measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "12"}, {"groupId": "BG003", "value": "12"}, {"groupId": "BG004", "value": "49"}]}]}, {"title": "Greater Than or Equal to (>=) 8", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "2"}, {"groupId": "BG004", "value": "10"}]}]}]}, {"title": "Duration of Diabetes", "paramType": "MEDIAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "16.8", "lowerLimit": "3", "upperLimit": "48"}, {"groupId": "BG001", "value": "23.9", "lowerLimit": "2", "upperLimit": "54"}, {"groupId": "BG002", "value": "20.6", "lowerLimit": "5", "upperLimit": "47"}, {"groupId": "BG003", "value": "16.7", "lowerLimit": "6", "upperLimit": "44"}, {"groupId": "BG004", "value": "20.7", "lowerLimit": "2", "upperLimit": "54"}]}]}]}, {"title": "Basal Insulin Daily Dose", "description": "Number of participants analyzed for this baseline characteristics =15, 14, 15, and 13 for each reporting group, respectively.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "units per kilogram (U/kg)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0.309", "spread": "0.086"}, {"groupId": "BG001", "value": "0.283", "spread": "0.088"}, {"groupId": "BG002", "value": "0.341", "spread": "0.100"}, {"groupId": "BG003", "value": "0.267", "spread": "0.055"}, {"groupId": "BG004", "value": "0.301", "spread": "0.087"}]}]}]}, {"title": "Total Insulin Daily Dose", "description": "Number of participants analyzed for this baseline characteristics = 13, 13, 13, 13 for each reporting group, respectively.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "U/kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0.600", "spread": "0.237"}, {"groupId": "BG001", "value": "0.620", "spread": "0.179"}, {"groupId": "BG002", "value": "0.677", "spread": "0.204"}, {"groupId": "BG003", "value": "0.513", "spread": "0.115"}, {"groupId": "BG004", "value": "0.603", "spread": "0.193"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percentage of Time in Target Plasma Glucose Range (4.4-7.8 mmol/L [80-140 mg/dL])", "description": "Percentage of time with glucose within glycemic range (4.4-7.8 mmol/L) was assessed by the total time within glycemic range divided by the length of the assessment interval.", "populationDescription": "Continuous glucose monitoring (CGM) population: All participants who received at least 1 dose, had evaluable post-baseline CGM data, irrespective of compliance. Number of participants analyzed = participants with baseline, Weeks 7-8 (Period A) and/or Weeks 15-16 (Period B) CGM assessment. Missing data imputed using last observation carried forward.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of time", "timeFrame": "Up to Week 16 (assessed at Weeks 7-8 in Period A and Weeks 15-16 in Period B)", "groups": [{"id": "OG000", "title": "HOE901-U300 Combined", "description": "HOE901-U300 SC injection once daily in morning or evening for 8 weeks during treatment period A, followed by once daily in evening or morning for 8 weeks during treatment period B."}, {"id": "OG001", "title": "Lantus Combined", "description": "Lantus SC injection once daily in morning or evening for 8 weeks during treatment period A, followed by once daily in evening or morning for 8 weeks during treatment period B."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "27"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "31.75", "spread": "1.5"}, {"groupId": "OG001", "value": "30.99", "spread": "1.58"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Analysis was performed using a linear mixed model with treatment and period as fixed effects, and participant as random effect.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7304", "statisticalMethod": "Linear Mixed Model", "paramType": "Least Squares (LS) Mean Difference", "paramValue": "0.75", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.614", "ciUpperLimit": "5.124", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.179"}]}, {"type": "SECONDARY", "title": "Percentage of Time Above the Upper Limit of Glycemic Range (Greater Than [>] 7.8 mmol/L [(140 mg/dL])", "description": "Percentage of time with glucose above the upper limit of glycemic range (\\>7.8 mmol/L) was assessed by the total time above the upper limit of glycemic range divided by the length of the assessment interval.", "populationDescription": "CGM population. Number of participants analyzed = participants with baseline, Weeks 7, 8 (Period A), and/or Weeks 15, 16 (Period B) CGM assessment. Missing data imputed using last observation carried forward (LOCF).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of time", "timeFrame": "Up to Week 16 (assessed at Weeks 7-8 in Period A and Weeks 15-16 in Period B)", "groups": [{"id": "OG000", "title": "HOE901-U300 Combined", "description": "HOE901-U300 SC injection once daily in morning or evening for 8 weeks during treatment period A, followed by once daily in evening or morning for 8 weeks during treatment period B."}, {"id": "OG001", "title": "Lantus Combined", "description": "Lantus SC injection once daily in morning or evening for 8 weeks during treatment period A, followed by once daily in evening or morning for 8 weeks during treatment period B."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "27"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "58.24", "spread": "2.09"}, {"groupId": "OG001", "value": "57.38", "spread": "2.2"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Time Below The Lower Limit of Glycemic Range (<4.4 mmol/L [80 mg/dL])", "description": "Percentage of time with glucose below the lower limit of glycemic range (\\<4.4 mmol/L) was assessed by the total time below the lower limit of glycemic range divided by the length of the assessment interval.", "populationDescription": "CGM population. Number of participants analyzed = participants with baseline, Weeks 7, 8 (Period A), and/or Weeks 15, 16 (Period B) CGM assessment. Missing data imputed using LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of time", "timeFrame": "Up to Week 16 (assessed at Weeks 7-8 in Period A and Weeks 15-16 in Period B)", "groups": [{"id": "OG000", "title": "HOE901-U300 Combined", "description": "HOE901-U300 SC injection once daily in morning or evening for 8 weeks during treatment period A, followed by once daily in evening or morning for 8 weeks during treatment period B."}, {"id": "OG001", "title": "Lantus Combined", "description": "Lantus SC injection once daily in morning or evening for 8 weeks during treatment period A, followed by once daily in evening or morning for 8 weeks during treatment period B."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "27"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10.01", "spread": "1.02"}, {"groupId": "OG001", "value": "11.64", "spread": "1.08"}]}]}]}, {"type": "SECONDARY", "title": "Evaluation of Diurnal Glucose Exposure, Variability, and Stability", "description": "The diurnal glucose exposure is measured as the average diurnal glucose concentration, diurnal glucose variability is measured by interquartile range (IQR), that is, average distance between the 25th and the 75th point-wise percentiles and diurnal glucose stability is assessed in terms of the mean absolute rate of change (mmol/l), that is, the area under the absolute rate of change of the median curve (based on the median point values between two adjacent hourly basket intervals), divided by the length of the assessment interval.", "populationDescription": "CGM population. Number of participants analyzed = participants with baseline, Weeks 7, 8 (Period A), and/or Weeks 15, 16 (Period B) CGM assessment. Missing data imputed using LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Up to Week 16 (assessed at Weeks 7-8 in Period A and Weeks 15-16 in Period B)", "groups": [{"id": "OG000", "title": "HOE901-U300 Combined", "description": "HOE901-U300 SC injection once daily in morning or evening for 8 weeks during treatment period A, followed by once daily in evening or morning for 8 weeks during treatment period B."}, {"id": "OG001", "title": "Lantus Combined", "description": "Lantus SC injection once daily in morning or evening for 8 weeks during treatment period A, followed by once daily in evening or morning for 8 weeks during treatment period B."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "27"}]}], "classes": [{"title": "Diurnal Glucose Exposure", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.869", "spread": "0.24"}, {"groupId": "OG001", "value": "8.910", "spread": "0.26"}]}]}, {"title": "Diurnal Glucose Stability", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.673", "spread": "0.03"}, {"groupId": "OG001", "value": "0.703", "spread": "0.03"}]}]}, {"title": "Diurnal Glucose Variability", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.931", "spread": "0.22"}, {"groupId": "OG001", "value": "5.279", "spread": "0.23"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Time in Target Plasma Glucose Range (4.4-7.8 mmol/L [80-140 mg/dL]) in the Last Four Hours of Each Dosing Interval at Weeks 7 and 8 in Period A and Weeks 15 and 16 in Period B", "description": "Percentage of time with glucose within glycemic range (4.4-7.8 mmol/L) was assessed by the total time within glycemic range divided by the length of the assessment interval.", "populationDescription": "CGM population. Number of participants analyzed = participants with baseline, Weeks 7, 8 (Period A), and/or Weeks 15, 16 (Period B) CGM assessment, and n = participants with assessment at specified time-point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of time", "timeFrame": "Weeks 7-8 in Period A and Weeks 15-16 in Period B", "groups": [{"id": "OG000", "title": "HOE901-U300 Combined", "description": "HOE901-U300 SC injection once daily in morning or evening for 8 weeks during treatment period A, followed by once daily in evening or morning for 8 weeks during treatment period B."}, {"id": "OG001", "title": "Lantus Combined", "description": "Lantus SC injection once daily in morning or evening for 8 weeks during treatment period A, followed by once daily in evening or morning for 8 weeks during treatment period B."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "27"}]}], "classes": [{"title": "Week 7, 8 (n=28, 27)", "categories": [{"measurements": [{"groupId": "OG000", "value": "32.08", "spread": "14.74"}, {"groupId": "OG001", "value": "29.07", "spread": "13.82"}]}]}, {"title": "Week 15, 16 (n=29, 26)", "categories": [{"measurements": [{"groupId": "OG000", "value": "33.02", "spread": "13.48"}, {"groupId": "OG001", "value": "28.70", "spread": "14.57"}]}]}]}, {"type": "SECONDARY", "title": "Change in HbA1c From Baseline to Week 8 and 16", "populationDescription": "Modified Intent-to-Treat population: randomized participants who received at least 1 dose; had baseline, at least 1 post-baseline efficacy assessment; irrespective of compliance. Number of participants analyzed = participants with baseline, Week 8 and/or 16 HbA1c assessment, n = participants with HbA1c assessment at specified time. LOCF applied.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of hemoglobin", "timeFrame": "Baseline, Week 8, 16", "groups": [{"id": "OG000", "title": "HOE901-U300 Combined", "description": "HOE901-U300 SC injection once daily in morning or evening for 8 weeks during treatment period A, followed by once daily in evening or morning for 8 weeks during treatment period B."}, {"id": "OG001", "title": "Lantus Combined", "description": "Lantus SC injection once daily in morning or evening for 8 weeks during treatment period A, followed by once daily in evening or morning for 8 weeks during treatment period B."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "27"}]}], "classes": [{"title": "Week 8 (n= 29, 20)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.22", "spread": "0.48"}, {"groupId": "OG001", "value": "-0.23", "spread": "0.54"}]}]}, {"title": "Week 16 (n= 28, 27)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.44", "spread": "0.51"}, {"groupId": "OG001", "value": "-0.22", "spread": "0.58"}]}]}]}, {"type": "SECONDARY", "title": "Change in Fasting Plasma Glucose (FPG) From Baseline to Week 8 and 16", "populationDescription": "Modified Intent-to-Treat population. Number of participants analyzed = participants with baseline, Week 8 and/or 16 FPG assessment, n = participants with FPG assessment at specified time. Missing data imputed using LOCF.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline, Week 8, 16", "groups": [{"id": "OG000", "title": "HOE901-U300 Combined", "description": "HOE901-U300 SC injection once daily in morning or evening for 8 weeks during treatment period A, followed by once daily in evening or morning for 8 weeks during treatment period B."}, {"id": "OG001", "title": "Lantus Combined", "description": "Lantus SC injection once daily in morning or evening for 8 weeks during treatment period A, followed by once daily in evening or morning for 8 weeks during treatment period B."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "23"}]}], "classes": [{"title": "Week 8 (n=24, 23)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.89", "spread": "5.04"}, {"groupId": "OG001", "value": "-0.10", "spread": "5.81"}]}]}, {"title": "Week 16 (n= 24, 22)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.99", "spread": "5.27"}, {"groupId": "OG001", "value": "0.78", "spread": "4.92"}]}]}]}, {"type": "SECONDARY", "title": "Change in Average 7-Point Self-Monitored Plasma Glucose (SMPG) Profile From Baseline to Week 8 and 16", "description": "Change in average of 7-point SMPG. 7-point SMPG was assessed starting with a measurement at before breakfast and 2 hours after breakfast\u037e before and 2 hours after lunch\u037e before and 2 hours after dinner\u037e at bedtime.", "populationDescription": "Modified Intent-to-Treat population. Number of participants analyzed = participants with baseline, Week 8 and/or 16 7-point SMPG assessment, n = participants with 7-point SMPG assessment at specified time. Missing data imputed using LOCF.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline, Week 8, 16", "groups": [{"id": "OG000", "title": "HOE901-U300 Combined", "description": "HOE901-U300 SC injection once daily in morning or evening for 8 weeks during treatment period A, followed by once daily in evening or morning for 8 weeks during treatment period B."}, {"id": "OG001", "title": "Lantus Combined", "description": "Lantus SC injection once daily in morning or evening for 8 weeks during treatment period A, followed by once daily in evening or morning for 8 weeks during treatment period B."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "22"}]}], "classes": [{"title": "Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.39", "spread": "1.84"}, {"groupId": "OG001", "value": "0.39", "spread": "1.54"}]}]}, {"title": "Week 16", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.47", "spread": "1.31"}, {"groupId": "OG001", "value": "0.58", "spread": "2.13"}]}]}]}, {"type": "SECONDARY", "title": "Change in Basal Insulin Daily Dose From Baseline to Week 8 and 16", "populationDescription": "Modified Intent-to-Treat population. Here n = participants with basal insulin dose assessment at specified time-point. Missing data imputed using LOCF.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "U/kg", "timeFrame": "Baseline, Week 8, 16", "groups": [{"id": "OG000", "title": "HOE901-U300 Combined", "description": "HOE901-U300 SC injection once daily in morning or evening for 8 weeks during treatment period A, followed by once daily in evening or morning for 8 weeks during treatment period B."}, {"id": "OG001", "title": "Lantus Combined", "description": "Lantus SC injection once daily in morning or evening for 8 weeks during treatment period A, followed by once daily in evening or morning for 8 weeks during treatment period B."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "29"}]}], "classes": [{"title": "Week 8 (n= 30, 29)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.06", "spread": "0.09"}, {"groupId": "OG001", "value": "0.03", "spread": "0.09"}]}]}, {"title": "Week 16 (n=29, 27)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.05", "spread": "0.09"}, {"groupId": "OG001", "value": "0.03", "spread": "0.08"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline Up to Week 16", "description": "Hypoglycemia events were Severe hypoglycemia (an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions)\u037e Documented symptomatic hypoglycemia (typical symptoms of hypoglycemia with plasma glucose level of \\<=3.9 mmol/L \\[70 mg/dL\\])\u037e Asymptomatic hypoglycemia (no typical symptoms of hypoglycemia but plasma glucose level \\<=3.9 mmol/L)\u037e Probable symptomatic hypoglycemia (an event during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination, but was presumably caused by a plasma glucose level \\<=3.9 mmol/L, symptoms treated with oral carbohydrate without a test of plasma glucose)\u037e Relative hypoglycemia (an event during which the person with diabetes reported any of the typical symptoms of hypoglycemia, and interpreted the symptoms as indicative of hypoglycemia, but plasma glucose level \\>3.9 mmol/L)\u037e Severe and/or confirmed a hypoglycemia (plasma glucose \\<=3.9 mmol/L).", "populationDescription": "Safety population: all randomized participants who were exposed to at least one dose, regardless of amount of treatment administered. In the event of participants having received treatments different from those assigned according to the randomization schedule, safety analyses were conducted according to treatment received.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Up to Week 16", "groups": [{"id": "OG000", "title": "HOE901-U300 Combined", "description": "HOE901-U300 SC injection once daily in morning or evening for 8 weeks during treatment period A, followed by once daily in evening or morning for 8 weeks during treatment period B."}, {"id": "OG001", "title": "Lantus Combined", "description": "Lantus SC injection once daily in morning or evening for 8 weeks during treatment period A, followed by once daily in evening or morning for 8 weeks during treatment period B."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "29"}]}], "classes": [{"title": "Any Hypoglycemia Event: All Hypoglycemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "100"}, {"groupId": "OG001", "value": "100"}]}]}, {"title": "Severe Hypoglycemia: All Hypoglycemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.3"}, {"groupId": "OG001", "value": "10.3"}]}]}, {"title": "Documented Symptomatic: All Hypoglycemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "93.3"}, {"groupId": "OG001", "value": "96.6"}]}]}, {"title": "Asymptomatic: All Hypoglycemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "86.7"}, {"groupId": "OG001", "value": "96.6"}]}]}, {"title": "Probable Symptomatic: All Hypoglycemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "16.7"}, {"groupId": "OG001", "value": "27.6"}]}]}, {"title": "Relative: All Hypoglycemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0"}, {"groupId": "OG001", "value": "6.9"}]}]}, {"title": "Severe and/or Confirmed: All Hypoglycemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "100"}, {"groupId": "OG001", "value": "100"}]}]}, {"title": "Any Hypoglycemia Event: Nocturnal Hypoglycemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "80.0"}, {"groupId": "OG001", "value": "93.1"}]}]}, {"title": "Severe Hypoglycemia: Nocturnal Hypoglycemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0"}, {"groupId": "OG001", "value": "6.9"}]}]}, {"title": "Documented Symptomatic: Nocturnal Hypoglycemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "66.7"}, {"groupId": "OG001", "value": "79.3"}]}]}, {"title": "Asymptomatic: Nocturnal Hypoglycemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "40.0"}, {"groupId": "OG001", "value": "48.3"}]}]}, {"title": "Probable Symptomatic: Nocturnal Hypoglycemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.3"}, {"groupId": "OG001", "value": "10.3"}]}]}, {"title": "Relative: Nocturnal Hypoglycemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0"}, {"groupId": "OG001", "value": "6.9"}]}]}, {"title": "Severe and/or Confirmed: Nocturnal Hypoglycemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "80.0"}, {"groupId": "OG001", "value": "93.1"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 16) regardless of seriousness or relationship to investigational product.", "description": "Reported adverse events are treatment-emergent adverse events that is AEs that developed/worsened during the 'on treatment period' (the time from first dose of study drug up to 2 days after the last dose of study drug). Analysis was done on safety population.", "eventGroups": [{"id": "EG000", "title": "HOE901-U300 Combined", "description": "HOE901-U300 SC injection once daily in morning or evening for 8 weeks during treatment period A, followed by once daily in evening or morning for 8 weeks during treatment period B.", "seriousNumAffected": 1, "seriousNumAtRisk": 30, "otherNumAffected": 18, "otherNumAtRisk": 30}, {"id": "EG001", "title": "Lantus Combined", "description": "Lantus SC injection once daily in morning or evening for 8 weeks during treatment period A, followed by once daily in evening or morning for 8 weeks during treatment period B.", "seriousNumAffected": 0, "seriousNumAtRisk": 29, "otherNumAffected": 17, "otherNumAtRisk": 29}], "seriousEvents": [{"term": "Intestinal obstruction", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 29}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 29}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 29}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 29}]}, {"term": "Migraine", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 29}]}, {"term": "Sinus congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 29}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 29}]}, {"term": "Nasal congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 29}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 29}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 29}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 29}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 29}]}, {"term": "Implant site bruising", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 29}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 29}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 29}]}, {"term": "Weight increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 29}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights."}, "pointOfContact": {"title": "Trial Transparency Team", "organization": "Sanofi", "email": "Contact--US@sanofi.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003922", "term": "Diabetes Mellitus, Type 1"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}, {"id": "D000001327", "term": "Autoimmune Diseases"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7117", "name": "Diabetes Mellitus, Type 1", "asFound": "Type 1 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}, {"id": "M4629", "name": "Autoimmune Diseases", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000007328", "term": "Insulin"}, {"id": "C000557859", "term": "Insulin, Globin Zinc"}, {"id": "D000069036", "term": "Insulin Glargine"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "asFound": "Blood", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "asFound": "Blood", "relevance": "HIGH"}, {"id": "M347", "name": "Insulin Glargine", "asFound": "Interaction", "relevance": "HIGH"}, {"id": "M17768", "name": "Zinc", "relevance": "LOW"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Micro", "name": "Micronutrients"}]}}, "hasResults": true}